Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03431896 · ClinicalTrials.gov registry record
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
A clinical trial of Amyloidosis and AL Amyloidosis, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- 37
- Enrollment target
- 1
- Study location
NCT03431896 is a study of Amyloidosis and AL Amyloidosis that has completed, run by The Cleveland Clinic. The registered enrollment target is 37 participants, below the 1,128-participant average among 28 other Amyloidosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03431896, a study of Amyloidosis and AL Amyloidosis, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
This study measures circulating, misfolded ATTR oligomers in asymptomatic ATTRm amyloidosis genetic carriers longitudinally over five years.
Conditions Studied
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2026-03-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03431896
The ClinicalTrials.gov registry entry for NCT03431896 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,128-participant average among 28 other Amyloidosis trials with a reported enrollment target (97% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Amyloidosis appearing as the primary indexed condition, and to 0 interventions.
NCT03431896 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03431896 about?
NCT03431896 is a clinical study titled "Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis". This study measures circulating, misfolded ATTR oligomers in asymptomatic ATTRm amyloidosis genetic carriers longitudinally over five years.
What is the current status of trial NCT03431896?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2018-02-01. Estimated completion is 2026-03-09.
What conditions does trial NCT03431896 study?
This clinical trial studies the following conditions: Amyloidosis, AL Amyloidosis, Transthyretin Amyloidosis, Amyloid Cardiomyopathy, Amyloid.
Who is sponsoring clinical trial NCT03431896?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03431896 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
RECRUITING · Phase 2
-
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
RECRUITING
-
A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography
RECRUITING
-
Dietary Reporting in the Amyloidoses
RECRUITING · NA
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.